You are here

Article info

Article menu

Download PDFPDF

Rheumatoid arthritis
Original research
COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs

Authors

  • Jih-Jin Tsai Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanSchool of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan PubMed articlesGoogle scholar articles
  • Li-Teh Liu Department of Medical Laboratory Science and Biotechnology, College of Medical Technology, Chung Hwa University of Medical Technology, Tainan, Taiwan PubMed articlesGoogle scholar articles
  • Chun-Hong Chen National Mosquito-Borne Diseases Control Research Center, National Health Research Institutes, Zhunan, TaiwanNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan PubMed articlesGoogle scholar articles
  • Liang-Jen Chen Department of Family Medicine, Pingtung Christian Hospital, Pingtung, Taiwan PubMed articlesGoogle scholar articles
  • Shiow-Ing Wang Center for Health Data Science, Department of Medical Research, Chung Shan Medical University Hospital, Taichung, TaiwanInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan PubMed articlesGoogle scholar articles
  • James Cheng-Chung Wei Institute of Medicine, Chung Shan Medical University, Taichung, TaiwanDepartment of Allergy Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, TaiwanDepartment of Nursing, Chung Shan Medical University, Taichung, TaiwanGraduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan PubMed articlesGoogle scholar articles
  1. Correspondence to Dr James Cheng-Chung Wei; jccwei{at}gmail.com; Dr Shiow-Ing Wang; shiowing0107{at}gmail.com
View Full Text

Citation

Tsai J, Liu L, Chen C, et al
COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
RMD Open 2023;9:e003038. doi: 10.1136/rmdopen-2023-003038

Publication history

  • Received January 28, 2023
  • Accepted June 30, 2023
  • First published July 21, 2023.
Online issue publication 
July 21, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.